Multipotent adult stem cells

• US 7,659,118 B2
• Filed: 09/29/2005
• Issued: 02/09/2010
• Est. Priority Date: 08/05/1999
• Status: Active Grant

• Current Assignee: ABT Holding Company (Athersys, Inc.)
• Original Assignee: ABT Holding Company (Athersys, Inc.), Regents of The University of Minnesota (University of Minnesota)
• Inventors: Verfaillie, Catherine M., Furcht, Leo T., Reyes, Morayma
• Primary Examiner(s): Lankford; L Blaine
• Assistant Examiner(s): LANKFORD JR, LEON B
• Application Number:
  US11/238,234
• Publication Number:
  US 20060030041A1
• Time in Patent Office: 1,594 Days
• Field of Search: 435/372, 435/366, 435/325
• US Class Current: 435/366
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 2039/5156 expressing foreign proteins
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 39/461 characterised by the cell type used
• CPC Class Codes: A61K 39/46432 Nervous system antigens
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C12N 2501/105 Insulin-like growth factors [IGF]
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 2501/235 Leukemia inhibitory factor [LIF]
• CPC Class Codes: C12N 2503/00 Use of cells in diagnostics
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 5/0607 Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12Y 207/07049 RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Abstract

The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.

Claims

1. A cell culture comprising isolated expanded human multipotent, non-embryonic, non-germ cells that can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages and express telomerase, said cells having undergone at least 10-40 cell doublings in culture.

3. The cell culture of claim 1 or 2 wherein the telomerase-expressing cells have undergone 10 cell doublings.

4. The cell culture of claim 1 or 2 wherein the telomerase-expressing cells have undergone 20 cell doublings.

5. The cell culture of claim 1 or 2 wherein the telomerase-expressing cells have undergone 30 cell doublings.

6. The cell culture of claim 1 or 2 wherein the telomerase-expressing cells have undergone 40 cell doublings.

7. The cell culture of claim 1 or 2, wherein the cells are genetically modified.

8. The cell culture of claim 7 wherein the modification comprises introducing a selectable or screenable marker gene into the cells.

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and isolated expanded human multipotent, non-embryonic, non-germ cells that can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages and express telomerase, said cells having undergone at least 10-40 cell doublings in culture, said cells obtained from the cell culture of claim 1 or 2.

10. A method for making a pharmaceutical composition comprising admixing a pharmaceutically acceptable carrier and isolated expanded human multipotent, non-embryonic, non-germ cells that can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages and express telomerase, said cells having undergone at least 10-40 cell doublings in culture, said cells obtained from the cell culture of claim 1 or 2.

11. A method for making the cell culture of claim 1 or 2, said method comprising introducing the telomerase-expressing cells into cell culture medium and expanding said cells such that said cells undergo at least 10-40 cell doublings in culture.

12. The cell culture of claim 1 or 2 wherein the telomerase-expressing cells have undergone greater than 40 cell doublings.

2. A cell culture comprising isolated expanded human multipotent, non-embryonic, non-germ, cells that can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages, express telomerase, and have been obtained by culture of non-embryonic, non-germ tissue, the telomerase-expressing cells having undergone at least 10-40 cell doublings in culture.